课题基金 / 基金详情

Interactions of the SV40 Small T Antigen and PP2A in Human Cell Transformation

Interactions of the SV40 Small T Antigen and PP2A in Human Cell Transformation
SV40 小 T 抗原和 PP2A 在人类细胞转化中的相互作用
批准号:
7223407
负责人:
WILLIAM C HAHN
金额:
$17.3万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:

项目摘要

项目成果

WILLIAM C HAHN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
We now understand neoplastic transformation to be the consequence of multiple acquired genetic alterations. These changes in aggregate confer the various phenotypes that constitute the clinical features of cancer. Although only rare human cancers derive from a viral etiology, the study of DNA tumor viruses that transform rodent and human cells has led to a greater understanding of the molecular events that program the malignant state. In particular, investigation of the viral oncoproteins specified by the Simian Virus 40 Early Region (SV40 ER) has revealed critical host cell pathways, whose perturbation play an essential role in the experimental transformation of mammalian cells. Our recent work has re-investigated the roles of two SV40 ER oncoproteins, the large T antigen (T) and the small t antigen (t), in human cell transformation. Co-expression of these two oncoproteins, together with the telomerase catalytic subunit, hTERT, and an oncogenic version of the H-RAS oncoprotein, suffices to transform human cells. T inactivates two key tumor suppressor pathways by binding to the retinoblastoma protein (pRB) and p53. The ability of t to transform human cells requires interactions with specific subunits of the heterotrimeric protein phosphatase 2A (PP2A), an abundant family of serine-threonine phosphatases. In this application, we propose to use molecular biological, genetic, and biochemical approaches to investigate the molecular interactions that lead to human cell transformation by t. Investigating the consequences of the interaction of t with PP2A will identify new pathways critical for cancer development as well as novel targets for cancer therapeutics.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of p300/CBP histone acetyltransferase inhibitors for oncogene-driven cancers
  • 批准号:
    10344246
  • 项目类别:
  • 资助金额:
    $68.27万
  • 财政年份:
    2022
  • 负责人:
    WILLIAM C HAHN
  • 依托单位:
Development and implementation of multiplex methods to understand the biology and heterogeneity of patient-derived cancer models
  • 批准号:
    10186722
  • 项目类别:
  • 资助金额:
    $96.32万
  • 财政年份:
    2020
  • 负责人:
    WILLIAM C HAHN
  • 依托单位:
Development and implementation of multiplex methods to understand the biology and heterogeneity of patient-derived cancer models
  • 批准号:
    10458506
  • 项目类别:
  • 资助金额:
    $96.37万
  • 财政年份:
    2020
  • 负责人:
    WILLIAM C HAHN
  • 依托单位:
PROJECT 4: Interrogating PP2A Signaling in Human Cancers
  • 批准号:
    10227785
  • 项目类别:
  • 资助金额:
    $32.64万
  • 财政年份:
    2017
  • 负责人:
    WILLIAM C HAHN
  • 依托单位:
海外基金